News & Media

Latest News

Filter Your Search

Targeted Oral Therapy Combo Safe, Effective for Both Never-Treated and Relapsed Chronic Lymphocytic Leukemia

Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, a newer class of drugs shown to improve the survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Read More

Acalabrutinib is a second-generation Bruton's tyrosine kinase (BTK) inhibitor, a newer class of drugs shown to improve the survival of patients with chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Read More

Second Generation BTK Inhibitor Highly Effective Safe as Solo Therapy in Adult Leukemia

Updated data on the first 134 chronic lymphocytic leukemia patients treated with single-agent acalabrutinib shows that the drug was well-tolerated in the majority of patients treated and responses were durable over time, according to researchers at the OSUCCC – James. Read More

Updated data on the first 134 chronic lymphocytic leukemia patients treated with single-agent acalabrutinib shows that the drug was well-tolerated in the majority of patients treated and responses were durable over time, according to researchers at the OSUCCC – James. Read More

Triple Drug Treatment Combo Shows Promise in Adult Leukemia

A triple-drug targeted therapy approach could offer an effective new treatment option for chronic lymphocytic leukemia (CLL) that reduces the risk for the long-term side effects experienced with chemotherapy and is given for a limited time, not as a daily lifetime drug therapy. Read More

A triple-drug targeted therapy approach could offer an effective new treatment option for chronic lymphocytic leukemia (CLL) that reduces the risk for the long-term side effects experienced with chemotherapy and is given for a limited time, not as a daily lifetime drug therapy. Read More

Researchers Invent Novel RNA Nanotech to Decorate Exosomes for Effective Cancer Therapy

A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics such as small interfering RNA (siRNA) specifically to cancer cells. Read More

A new study shows that attaching antibody-like RNA nanoparticles to microvesicles can deliver effective RNA therapeutics such as small interfering RNA (siRNA) specifically to cancer cells. Read More

Search Our Media Library

See All Images

Contact Media Staff

Amanda Harper

Director of Media Relations


614-685-5420 (direct)


614-293-3737 (main)


Amanda.Harper2@osumc.edu


Media staff are available by calling 614-293-3737 Monday through Friday between 8 a.m. and 5 p.m.

 

If after hours, please call 614-293-8000 (ask the operator to page the hospital administrative manager).